SCHEMBL18415083

SCHEMBL18415083

COc1c(-c2nnc(C)o2)cccc1C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
BRD4 O60885 1/20 0.42
PDK2 Q15119 1/20 0.41
TYK2 P29597 2/20 0.39
JAK1 P23458 1/20 0.38
NPC1 O15118 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17194992 0.81 PDK2 (0.45) SMN1; SMN2RAB9ABRD4PDK2NPC1
SCHEMBL15698698 0.81 RAB9A (0.50) SMN1; SMN2RAB9ANPSR1BRD4PDK2
SCHEMBL29133096 0.79 RAB9A (0.44) SMN1; SMN2RAB9ANPSR1BRD4PDK2
SCHEMBL15698590 0.79 BRD4 (0.43) SMN1; SMN2RAB9ANPSR1BRD4PDK2
SCHEMBL30622190 0.79 RAB9A (0.44) SMN1; SMN2RAB9ANPSR1BRD4PDK2
SCHEMBL17198745 0.77 BRD4 (0.45) SMN1; SMN2RAB9ANPSR1BRD4PDK2
SCHEMBL15689483 0.73 RAB9A (0.53) SMN1; SMN2RAB9ANPSR1BRD4TYK2
SCHEMBL18415113 0.72 TYK2 (0.39) SMN1; SMN2RAB9ATYK2NPC1KDM4E
SCHEMBL13393606 0.71 BRD4 (0.63) SMN1; SMN2RAB9ABRD4NPC1KDM4E
SCHEMBL3096012 0.71 CA2 (0.50) SMN1; SMN2KDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021475-B2 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses BRISTOL-MYERS SQUIBB COMPANY (US) 2021-06-01 US disclosed
US-20200071315-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL-MYERS SQUIBB COMPANY 2020-03-05 US disclosed
US-10000480-B2 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses BRISTOL-MYERS SQUIBB COMPANY (US) 2018-06-19 US disclosed
US-9987266-B2 Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses BRISTOL-MYERS SQUIBB COMPANY (US) 2018-06-05 US disclosed
US-20170209426-A1 ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES BRISTOL MYERS SQUIBB CO (US) 2017-07-27 US disclosed
US-9663467-B2 Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-30 US disclosed
US-20170022192-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL-MYERS SQUIBB COMPANY 2017-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000480-B2 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses IFNG, IFNAR1, TYK2 SMN1; SMN2 3786/4885RAB9A 2002/4885NPSR1 2539/4885
US-11021475-B2 Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses IFNG, IFNAR1, TYK2 SMN1; SMN2 3786/4885RAB9A 2002/4885NPSR1 2539/4885
US-20170022192-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES IFNG, IFNAR1, TYK2 SMN1; SMN2 3786/4885RAB9A 2002/4885NPSR1 2539/4885
US-20170209426-A1 ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES IFNAR1, TYK2, IFNG SMN1; SMN2 3708/4885RAB9A 2115/4885NPSR1 2581/4885
US-20200071315-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES IFNG, IFNAR1, TYK2 SMN1; SMN2 3786/4885RAB9A 2002/4885NPSR1 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.